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An intimate connection between inﬂ ammation and 
cancer has been proposed for decades based upon both 
biological similarities and clinical observation. Numerous 
autoimmune diseases are associated with neoplasia, with 
an elevated risk of lymphoma in Sjögren’s syndrome [1] 
and rheumatoid arthritis [2], and gastrointestinal inﬂ am-
mation in Crohn’s disease and ulcerative colitis is likewise 
associated with increased risk of intestinal neoplasia [3]. 
Inﬂ ammation induced by infectious organisms may also 
result in neoplasia, as exempliﬁ ed by the association of 
Helicobacter pylori infection and gastric cancer, hepatitis 
C virus and hepatic cancer [4] and schistosomiasis and 
bladder cancer [5]. It has been estimated that 15% of 
malignancies may be caused by an underlying infection 
[6].
One of the most fundamental biological similarities 
between inﬂ ammation and cancer is the presence of 
similar inﬂ ammatory cells in these processes, and on 
occasions these immune cells have been demonstrated to 
be essential for tumour progression. Mast cells, for 
example, are required for tumour growth in a model of 
pancreatic cancer [7] and macrophages promote invasive, 
metastatic behaviour in murine mammary cancer [8]. 
Th e importance of these cellular similarities is under-
scored by the observation that inhibition of tyrosine 
kinase activity with imatinib is an established therapeutic 
strategy in systemic mastocytosis [9] and chronic myeloid 
leukaemia [10], but has also been reported to be eﬀ ective 
in rheumatoid arthritis [11-13]. Tumours frequently 
manipulate the host immune response - for example, by 
secreting chemokines to induce a tolerogenic cellular 
microenvironment  - and may stimulate angiogenesis 
through elaboration of inﬂ ammatory cytokines [14]. As 
well as cells, inﬂ ammatory signalling molecules such as 
NF-kB are often shared between neoplastic and inﬂ am-
matory conditions, and these molecules promote both 
processes. Th us, inactivation of this pathway in intestinal 
epithelial cells results in a direct reduction of tumour 
incidence, whereas its inactivation in myeloid cells, which 
cause inﬂ ammation, results in a reduction of pro-
inﬂ ammatory cytokines and resultant decrease in tumour 
size [15]. Similarly, both NF-κB and STAT-3 signalling 
pathways have been strongly implicated in hepatoma 
development [16]. Further examples of the shared role of 
molecules in neoplasia and inﬂ ammatory arthritis 
include the Myc oncoprotein, which has also been shown 
to induce angiogenesis through the elaboration of IL-1β 
[17]. As well as this role in tumour vascularisation, this 
cytokine contributes to inﬂ ammation in rheumatoid 
arthritis, as indicated by the eﬀ ects of IL-1β neutralisation 
in this disease [18]. Given the importance of the signal-
ling pathway that operates through the mammalian target 
of rapamycin (mTOR) in both immune and neoplastic 
cells, attention is currently focussed on therapeutic 
approaches centred on this molecule for both auto-
immune and neoplastic pathologies [19,20].
Suggestions of a causal role of inﬂ ammation in cancer 
emerge from the observation that the development of 
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It is well established that an intimate connection 
exists between infl ammation and neoplasia. Indeed, 
particular chronic infections and autoimmune 
processes giving rise to prolonged site-specifi c 
infl ammation are known to increase the probability 
of the development of specifi c cancers. Molecular 
characterisation of these processes has revealed 
profound similarities in the specifi c molecules 
involved in persistence of infl ammation and in both 
the primary induction of neoplastic processes and 
in specifi cation of the preferred anatomic sites of 
metastatic spread. The therapeutic importance of these 
fi ndings is underscored by the remarkable success 
in the treatment of autoimmune pathology using 
medications initially developed for use in oncology and 
this arena is one of considerable therapeutic promise 
for rheumatologists.
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neoplasia in response to inﬂ ammation is strongly asso-
ciated with the chronicity and intensity of the inﬂ am-
matory stimulus. Patients with high disease activity in 
rheumatoid arthritis thus have the highest chance of 
developing lymphoma [2]. Indeed, pro-inﬂ ammatory 
molecules produced within inﬂ ammatory lesions can 
themselves directly promote genomic instability, as 
exempliﬁ ed by reactive oxygen and nitrogen species that 
result in DNA damage [21]. Early experiments demon-
strated that culture with neutrophils elaborating reactive 
oxygen species endows ﬁ broblasts with an ability to 
induce tumour development when transferred into mice 
[22]. Moreover, the rapid cell proliferation asso ciated 
with inﬂ ammation results in further cellular susceptibility 
to DNA damage in an environment where, in addition, 
DNA repair processes are themselves com promised. Co-
culture of activated neutrophils with human alveolar 
epithelial cells reveals that neutrophils and the hypo-
chlorous acid that they produce can strongly inhibit 
nucleotide excision repair (NER) of damaged DNA and 
this eﬀ ect can be abrogated by inhibiting production of 
hypochlorous acid [23]. Inﬂ ammatory cells, moreover, 
express tissue degradative enzymes and promote angio-
genesis, processes that aid neoplastic cells to metastasise.
Th at inﬂ ammation itself can induce genetic mutation 
and thus predispose to neoplastic development is 
demonstrated by the spontaneous inﬂ ammatory bowel 
disease that develops in interleukin-10 deﬁ cient mice, 
since this is associated with a colonic mutation rate ﬁ ve 
times greater than wild-type mice, with a ten-fold 
increase in small deletions and insertions to DNA [24]. 
Indeed, mutations of p53 are found in both human 
inﬂ ammatory bowel disease [25] and rheumatoid 
synovium [26]. In addition to compromised p53 activity 
through mutation, this molecule can also be functionally 
inhibited by the pro-inﬂ ammatory molecule macrophage 
migration inhibitory factor [27], demonstrating another 
important means by which inﬂ ammation, if unchecked, 
can potentially induce dysregulated cellular proliferation.
Th e shared use of chemokine receptors in driving both 
tissue-speciﬁ c inﬂ ammation and tissue-speciﬁ c meta-
stases of neoplastic cells has received increasing atten-
tion. Indeed, the chemokine receptors CXCR4 and CCR7 
are expressed on breast cancer tumours and metastases, 
and their ligands highly expressed in the preferential 
metastatic sites [28]. Diﬀ erential expression of chemokine 
receptors on diﬀ erent tumours and their ligands in 
metastatic sites explains the diﬀ erential patterns of 
metastases, just as these molecules co-ordinate immune 
cell traﬃ  cking.
Th e extremely potent pro-inﬂ ammatory cytokine IL-23 
demonstrates a further central connection between 
autoimmune disease and cancer. Th is cytokine is central 
to autoimmune inﬂ ammation and has been shown to 
play a fundamental role in spondyloarthropathy, for 
which it is a promising therapeutic target [29]. However, 
IL-23 is also expressed within the vast majority of human 
carcinomas, where it promotes inﬂ ammation and 
expression of degradative enzymes such as MMP9 [30]. 
In neoplastic settings, IL-23 inhibits protective anti-
tumour immunity. In addition to IL-23, other pro-
inﬂ ammatory cytokines have been demonstrated to be 
important in promoting neoplasia, with TNF, IL-1 and 
IL-6 playing key roles in ovarian cancer [31], and these 
molecules are established therapeutic targets that are 
neutralised in routine clinical practice for rheumatoid 
arthritis [18,32,33].
Th e intimate connection between inﬂ ammation and 
cancer has encouraged the use of anti-inﬂ ammatory 
agents to halt neoplastic development. Indeed, aspirin 
has been shown to reduce the incidence of cancer [34] 
and mice with deﬁ ciency in the COX enzymes that this 
drug targets have reduced skin tumorigenesis [35]. 
Indeed, the reduced incidence of gastrointestinal and 
gynaecological cancers in rheumatoid arthritis patients 
has been attributed to non-steroidal anti-inﬂ ammatory 
drug (NSAID) use [36]. Many chemotherapeutic agents 
are in clinical use not only for treatment of cancer, but 
also for immune-mediated inﬂ ammation, prime examples 
being cyclophosphamide and methotrexate. Moreover, 
modern biological agents are also eﬃ  cacious in both 
settings. Th us, rituximab is used to treat haematological 
malignancy, being eﬀ ective in follicular and mantle cell 
lymphoma and diﬀ use large B cell lymphoma [37], but 
also signiﬁ cantly improves clinical outcomes in rheu ma-
toid arthritis [38]. Even TNF blockade, which some view 
as potentially facilitating oncogenesis, may also be viewed 
as protective against cancer development with recent 
studies conducted in renal cell and ovarian carcinoma 
[39-42].
Both inﬂ ammatory conditions [43] and cancer [44] are 
associated with extensive modulation of local stromal 
tissue, with elaboration of pro-inﬂ ammatory molecules. 
Moreover, the aforementioned mutations in p53 in 
rheumatoid synovium occur in islands of the intimal 
lining, most likely in type B ﬁ broblast-like synoviocytes, 
and this is associated with elevated production of IL-6, 
the latter itself driving inﬂ ammation. Indeed, inﬂ am ma-
tion itself is worse in mice deﬁ cient in p53, which develop 
more severe collagen-induced arthritis [45]. Given the 
success of agents targeting cancer-associated stromal 
cells in general and the ﬁ broblast markers FAP [46] and 
CD248 [47] in particular, targeting similar pathogenic 
stromal cells in immune-mediated inﬂ ammation has 
already shown [48], and is likely to continue to show, 
considerable promise.
Abbreviations
IL, interleukin; NF, nuclear factor; TNF tumour necrosis factor.
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